Xenikos starts Clinical Study at Radboudumc

Xenikos B.V. announced the start of a new clinical study in the Netherlands of T-Guard™ for treatment of Graft versus Host Disease (GVHD), a frequent and potentially life-threatening complication of bone marrow and blood stem cell transplantation. The Phase I/II trial began on January 6, 2014 following approval from the relevant Dutch authorities late in 2013.

The study is being conducted at Radboud university medical center in Nijmegen, the Netherlands.

Read the full press release more at website Xenikos